ReviewArchives of Razi Institute2025
Utilizing
Review in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HarnessingArchives of Razi Institute · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a persistent global health problem that necessitates innovative therapeutic approaches for effective intervention. In recent years, there has been a significant increase in research focusing on the potential anti-cancer properties of various filamentous Aspergillus molds. This review aims to systematically assess the scientific evidence regarding the potential anti-tumor effects of distinct Aspergillus species and their secondary metabolites in the context of lung cancer. A multitude of Aspergillus species, with Aspergillus fumigatus being a prominent example, have exhibited the capacity to generate compounds that hold considerable promise in the realm of anti-cancer therapeutics. Gliotoxin, a notable example, has been identified as a crucial agent inducing apoptosis in lung cancer cells while impeding tumor growth. Furthermore, Emericellamide A, a secondary metabolite derived from Aspergillus nidulans, exhibits significant toxicity against lung cancer cells. Serotonin, a natural product of Aspergillus terreus, has also been shown to have significant cytotoxic effects on lung cancer cells. Cycloopiazonic acid, a natural product of Aspergillus flavus, has exhibited significant anti-lung cancer properties, thus augmenting the existing repertoire of potential anti-cancer agents. The inhibitory effects on cancer cells extend beyond mere toxicity, involving processes such as apoptosis, regulation of angiogenesis, immune modulation, and suppression of proliferation. Despite the encouraging array of anti-cancer compounds presented by Aspergillus fungi, significant challenges persist in their identification, scalable production, and understanding of their interactions with existing therapeutic modalities. Addressing these challenges necessitates collaborative efforts, fostering synergy among researchers, clinicians, and industry stakeholders. Research into the pharmacological repertoire offered by Aspergillus fungi can only be successful with the concerted efforts of researchers to determine the best possible treatment options for lung cancer, leveraging the wide variety of therapeutic options available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.